AusCann‘s shares soared more than 40 per cent, after the Perth-based cannabis pharmaceutical company announced it was the latest player to run the regulatory gauntlet and produce a medicinal cannabis product.
The company has completed manufacturing and testing of its cannabinoid-based hard-shell capsules.
They are now undergoing clinical evaluation and the company expected the capsules to be available to the public in the first half of 2020.
“It’s no longer on an R&D bench, it is no longer some work we are doing in order to prove a hypothesis, it was done with large scale manufacturing, which is a major milestone for us because as soon as you scale up you need to make sure everything you have on the way from raw materials to manufacturing is consistent and reliable.”
Get the whole story here:
WA medical cannabis player finishes year on a high after product milestone